Observes acalabrutinib use in adults with chronic lymphocytic leukemia in Belarus
Studies how acalabrutinib is used in adults with chronic lymphocytic leukemia in routine care.
Plain-language title generated from the registry record
Registry title: Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
Key facts
- Where
- Grodno, Homyel, Minsk, and Mogilev, BelarusSee the 4 sites
Where in Belarus
- GrodnoGrodno, BelarusTaking people
- HomyelHomyel, BelarusNot yet recruiting
- MinskMinsk, BelarusTaking people
- MogilevMogilev, BelarusTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07288515
- Record updated
- 9 September 2026
- Original description
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLLRead full original descriptionShow less
Observational Prospective Study of Acalabrutinib in Chronic Lymphocytic Leukemia Therapy in Real Clinical Practice in Belarus.
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
Inclusion: Age ≥18 years; Confirmed diagnosis of CLL; Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation; Treatment-naïve or R/R CLL; Ability and willingness to provide informed consent for study participation.
Exclusion: Prior treatment with any BTK inhibitor; Patients not satisfying any of the inclusion criteria; Participation in other ongoing clinical trials; Pregnant or breastfeeding females.